Providers

Anthony Dorling qualified in Medicine from the University of London in 1987, did general medical training in hospitals around the South East of England and gained membership of the Royal College of Physicians in 1990.

He did his PhD under the supervision of Robert Lechler at the Royal Postgraduate Medical School, before embarking on specialist training in Nephrology in 1995.

He was appointed Senior Lecturer in Immunology at Imperial College London and honorary Consultant Nephrologist at the Hammersmith Hospital in 2001, becoming a Reader in 2005.

He was awarded fellowship of the Royal College of Physicians in the same year. He took up his current post in October 2009.

Richard Lane is Ambassador and Immediate Past President of Diabetes UK, the UK's leading diabetes charity.

Richard, who has Type 1 diabetes, was one of the first people in the UK to receive islet cell transplants in 2005.

The surgery came after a long history of diabetes-related complications, including comas and severe hypoglycaemic episodes (hypos).

The transplants transformed Richard’s life and he has not had a serious hypo since his first operation.

He was the first person in the UK to completely come off insulin. This situation continued for about a year, but he had then to go back on to insulin. He contracted a viral infection from which some antibodies developed which were damaging his new beta cells, and now he has to supplement his natural insulin via the pump and count carbs again.

Richard, who formerly held the position of President at Diabetes UK, has been a great advocate for the charity. He has spent much of his free time travelling the country undertaking public speaking at local community meetings and conferences to raise awareness of the condition and the work of Diabetes UK.

Professor Sehouli is a gynaecological oncologist, working at the Charité, University of Medicine in Berlin, Germany.

Professor Jalid Sehouli is currently the director of the department of gynecology in the famous Charité/ Campus Virchow-Klinikum and Campus Benjamin Franklin. He is also the head of the European Competence Center for Ovarian Cancer and is leading the gynaecological oncology at all three Campi at Charité Medical University in Berlin.

Professor Sehouli founded the German Foundation for ovarian cancer patients, being involved in many initiatives for patients.

Together with Professor Lichtenegger he founded the German north eastern society for gynaecological oncology (NOGGO). In 2000 he initiated the tumor bank ovarian cancer, which became the largest biobank for fresh frozen tissue worldwide.

Since 2013 Professor Sehouli was nominated as speaker for the OVAR Kommission of the AGO, Germany.

His clinical and scientific interest focuses on the surgical therapy and systemic treatment of advanced gynaecological malignancies. He lead several preclinical trials in predicting the surgical outcome. He is principle investigator in many Phase I to Phase III clinical trials in ovarian cancer.

He has published more than 250 national and international papers in the field of gynaecologic oncology.
He is a member of the executive board of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) and the Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie (NOGGO), and a member of the European Society of Gynaecological Oncology (ESGO), the Gynaecologic Cancer Intergroup (GCIG), the American Society of Clinical Oncology (ASCO) and the Multinational Association of Supportive Care in Cancer (MASCC).

Charlie Gourley graduated with honours in Genetics from the University of Glasgow in 1991. He then went on to qualify as a medical doctor in 1994 also at the University of Glasgow.

Charlie progressed through his medical training in Edinburgh, continuously combining that with active research interests. He has successfully held research positions both at the University of Edinburgh and within the NHS.

Charlie’s career ladder took him to his current position as a Professor and Honorary Consultant in Medical Oncology, specialising in gynaecological cancers. He leads a clinical research team at the Edinburgh Cancer Centre, and a translational research group at the University of Edinburgh Cancer Research UK Centre.

He is a member of the National Cancer Research Network gynaecological cancers clinical studies group, the National Cancer Research Network ovarian subgroup and the Scottish Gynaecological Cancers Trials Group. He is also an active member of several other committees.

Elena Ioana Braicu is a senior gynecologist at the Department for Gynecology Campus Vrchow, Charité Medical University Berlin. She is leading the translational research within this department, and coordinating the Tumor Bank for Ovarian Cancer network (www.toc-network.de).

She qualified in medicine in 2003 from “Iuliu Hatieganu” Medical University in Cluj-Napoca, Romania. She was research fellow at Max Delbrück Research center Berlin in 2003 and 2004, than at the Charité from 2005 and 2006 and at the University of Basel in 2008. Since 2009 she is working at the European Competence Center for Ovarian Cancer at the Charité Medical University.

She is representing the translational group of NOGGO, north eastern German society for gynecological oncology within ENGOT. She is a founding EUTROC member and is leading the working group for biobanking. She is also consultant for pediatric gynecology at the Charité Medical University.

Dr. Braicu participated in several European projects, like OVCAD (www.ovcad.eu) and OCTIPS (www.octips.eu). She is work package leader for biobanking and data repository in the Fp7 European Phase I/II clinical study, Gannet53 (www.gannet53.eu).

She is member in several national and international study groups (e.g. AGO, NOGGO, TOC, ENGOT, EUTROC, GCIG). She is member of the German Foundation of Ovarian Cancer.

Furthermore she is participating in several Phase I to Phase III clinical study as sub-investigator. She is the vice-coordinator of the clinical trial study center at the Charité Medical University.

Since 2013, she is a fellow of the clinical scientist program of the Charité Universitätsmedizin Berlin and the Berlin Institute of Health.

Her main interests are prevention and diagnostic of pelvic tumors in general and high risk population. She is focusing also in the discovery of predictive biomarkers for clinical outcome in ovarian cancer patients.

Christina Fotopoulou trained in obstetrics and gynecology and subspecialized in gynaecological oncology at the Charité University Hospital of Berlin in both the surgical and systemic treatment of women with advanced gynaecological malignancies and completed her PhD thesis entitled “Current Aspects in the Operative Treatment of Epithelial Ovarian Cancer”.

She is currently a Consultant Gynecological Oncologist and Adjunct Professor in the Imperial College London Healthcare Trust in Queen Charlottes Hospital in London and Ovarian Cancer Action Research center.

She has been the leading consultant and Vice Director of the Clinic for Gynecology at the Charité in Berlin, one of the largest reference and accredited centers for gynecological cancer in Germany, as well the Principal Coordinator of the European Competence Center for Ovarian Cancer, which was created in 2007 in Berlin.

Her principal area of clinical practice is in exenterative procedures for advanced forms of pelvic malignancies and in the cytoreductive debulking of primary or relapsed ovarian cancer. Furthermore, she was trained in the reconstructive surgery of oncologic patients after extensive exenterations.

Her area of research is the creation and validation of scores for optimal surgical quality, the analysis of tumour dissemination patterns, histopathological characteristics and surgical outcome in primary and relapsed of ovarian cancer and in the quality of life of patients after extensive operative procedures.

Christina Fotopoulou is a member of the German AGO- Ovarian Cancer Steering Group which is responsible for the generation of national guidelines for the management of ovarian cancer and borderline ovarian lesions. She is the surgical lead in the European Network for Translational Research in Ovarian Cancer (EUTROC) in the working package “Predicting surgical outcome”.

She has broad experience in national and international clinical and surgical trials in Germany and in innovative intraperitoneal immunotherapies in palliative stages of gynaecological malignancies.

She has lectured in many countries on her clinical research and surgical experience.

She is on the editorial board of two journals and reviewer in numerous international gynaecological and oncological journals and is member of various international oncological committees, including ASCO, ESGO, IGCS, ESMO, ENGOT, AGO and NOGGO.

EUTROC (European Translational Research network in Ovarian Cancer) is a European cancer network addressing the fragmentation currently hindering translational research for cutting edge therapies in ovarian cancer.

It will strengthen European excellence in the diagnosis and treatment of OC.

The need to bring promising drug candidates and treatments into clinical settings is currently delayed by the lack of standardised protocols for preclinical animal studies, lack of suitable ovarian cancer models, lack of validated predictive biomarker diagnostics, and integrated appropriate management of translational research partners (including pharma and biotech companies).

Developing effective diagnostic and treatment strategies require structured joint efforts of experts on tumor immunology, epigenetics, pathology, bioinformatics, drug development and delivery, trial development, clinical oncology and gynecological oncology.

Leading European researchers and clinicians together with the pharmaceutical industry and biotech companies will focus on preclinical and clinical studies in ovarian cancer. Therefore new targets will be identified, validated and translated to new drugs and brought to clinical practice. Standardisation and harmonisation of laboratory practices and good clinical practice procedures will BE performed within the consortium.

The consortium combines expertise in clinical as well as preclinical research. Involved researchers are coordinating a number of investigator-initiated Phase I, II trials.The Network will build a platform for research and strong educational programs for the next generation of experts aimed at developing individualised patients benefit.

Dr. Alessandro Giardini is a consultant paediatric cardiologist at Great ormond Street Hospital in London and specializes in the diagnosis and care of babies, children and adolescents with congenital heart disease.

Personal website  at: www.childheartspecialist.com

After qualifying as a doctor from the University of Malta in 2004 and completing her housemanship on the island, Dr. Raina Zarb Adami then moved to Sydney, where she gained post-graduate experience in general and plastic surgery. She became a member of the Royal College of Surgeons of Edinburgh in 2008.

Dr. Zarb Adami’s approach to non-invasive facial rejuvenation and sculpting is unrivalled. She brings passion for quality to a cosmetic practice where integrity, intelligence and striving for perfection flourish. Her artistic eye complements a thorough scientific and surgical expertise.

She is an advanced practitioner based in London with an integrated approach using Botox (Botulinum Toxin), dermal fillers for treatments like lip enhancement and non-surgical rhinoplasty, skin care, chemical peels and Dermaroller microneedling techniques for facial rejuvenation and enhancement.

Her background in plastic surgery allows Dr. Zarb Adami to provide mole removal, scar treatment and split earlobe repair, offering optimal cosmetic outcomes.

Dr. Zarb Adami continues to attend and present at numerous conferences and workshops in aesthetic medicine and plastic surgery, both nationally and internationally. She has been awarded The Professions Woman of the Future in The Woman of the Future Awards 2010 and the Rising Star Award at the Aesthetic Awards UK 2011-2012.

She has successfully trained many practitioners in cosmetic procedures, and is a certified lecturer on the subject through The Academy of Aesthetic Excellence based in London. Dr Zarb Adami has dedicated time to volunteering with an Australian plastic surgery team operating on victims of burn injuries in Nepal. She also regularly participates in various other international voluntary work projects.

She is currently undertaking a research project as a PhD with the charity organisation RAFT (Restoration of Appearance and Function Trust) to develop an artificial skin – the Smart Matrix – to treat patients suffering from burns and other chronic and complex wounds.

Niroshan Sivathasan completed his bachelor’s and medical degrees at the age of 23 from King’s College London and University College London, respectively.

His postgraduate qualifications in surgery and aesthetic medicine were also gained in London. He has published over 30 articles, and is a reviewer and editorial committee-member for various medical journals.

He has a particular interest in cosmesis, and is undertaking an international fellowship in cosmetic surgery.